면역 독소 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Immunotoxins Market Growth & Trends:

The global immunotoxins market size is expected to reach USD 243.3 million by 2030, registering a CAGR of 8.23% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of cancer and technological advancements are some of the factors anticipated to drive market growth.

Immunotoxins are a class of targeted therapeutics that combine a cytotoxic agent with a targeting moiety, such as an antibody or growth factor. The development of immunotoxins has gained momentum due to their potential effectiveness in treating various cancers and other diseases. Cancer is a growing concern worldwide, with an estimated 20 million new cases and 9.7 million deaths in 2022. Immunotoxins consist of an antibody fragment, or a targeting moiety linked to a toxin, which allows for selective delivery of the toxic agent directly to cancer cells. Moreover, the development and application of immunotoxins have evolved significantly over recent years, leading to various ongoing research initiatives aimed at improving their efficacy, reducing immunogenicity, and expanding their therapeutic applications. Researchers are identifying novel tumor-specific antigens that could serve as targets for new immunotoxin therapies.

The COVID-19 pandemic led to significant disruptions in global supply chains. Manufacturing facilities faced shutdowns or reduced operations due to health regulations and workforce shortages. This situation affected the availability of raw materials and components necessary for producing immunotoxins. Moreover, the pandemic fostered collaboration among pharmaceutical companies, academic institutions, and government entities to accelerate drug development processes, further propelling market growth.

However, one of the primary challenges associated with immunotoxin therapies is the potential for severe side effects. Patients may experience adverse reactions such as nausea, diarrhea, and fever. For instance, certain toxins like Ricin-based immunotoxins have been associated with severe complications such as capillary leak syndrome or hepatotoxicity. Such risks can lead to clinical trial terminations or regulatory hurdles during drug approval processes, further limiting market growth.

Immunotoxins Market Report Highlights:

• Based on product, Diphtheria Toxin (DT) segment dominated the product segment in the market with a market share of 43.91% in 2024. Diphtheria toxin has been used in cancer treatment as part of targeted therapies designed to attack cancer cells.
• Based on application, Therapy development is driving the growth of the market and is expected to see the fastest growth rate of 8.29% during the forecast period. This growth is driven by increasing investment in R&D, particularly in targeted cancer therapies, which offer more precise and effective treatment options.
• Based on end-use, Pharmaceutical and biotechnology companies are leading the immunotoxins market with a market share of 46.49% in 2024. This is mainly due to their significant investment in research and development to create new immunotoxins tailored for specific medical conditions.
• Based on region, North America immunotoxins market dominated the market and accounted for 41.45% share in 2024, attributed to the region's advanced healthcare infrastructure, strong presence of leading biotechnology firms, and significant funding for immunology and oncology research.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Product Segment
  • 1.2.2. Application Segment
  • 1.2.3. End Use Segment
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Immunotoxins Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of cancer
    • 3.2.1.2. Technological advancements
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Cytotoxic and manufacturing challenges associated with immunotoxins
• 3.3. Immunotoxins Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Immunotoxins Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Immunotoxins Market Product Movement Analysis
• 4.3. Global Immunotoxins Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Diphtheria Toxin (DT)
  • 4.4.1. Diphtheria toxin (DT) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Anthrax Based Toxins
  • 4.5.1. Anthrax based toxins market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Pseudomonas Exotoxin (PE)
  • 4.6.1. Pseudomonas exotoxin (PE) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Other Immunotoxins
  • 4.7.1. Other immunotoxins market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Immunotoxins Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Immunotoxins Market Application Movement Analysis
• 5.3. Global Immunotoxins Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Biomedical Research
  • 5.4.1. Biomedical research market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Therapy Development
  • 5.5.1. Therapy development market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Immunotoxins Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Immunotoxins Market End Use Movement Analysis
• 6.3. Global Immunotoxins Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Pharmaceutical & Biotechnology Companies
  • 6.4.1. Pharmaceutical & biotechnology companies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. CROs & CMOs
  • 6.5.1. CROs & CMOs market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Academic & Research Institutes
  • 6.6.1. Academic & research institutes market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Immunotoxins Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030
• 7.4. North America
  • 7.4.1. U.S.
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Competitive scenario
    • 7.4.1.3. Regulatory framework
    • 7.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Canada
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Regulatory framework
    • 7.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Mexico
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Regulatory framework
    • 7.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. UK
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Competitive scenario
    • 7.5.1.3. Regulatory framework
    • 7.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Germany
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. France
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Italy
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Regulatory framework
    • 7.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. Spain
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Regulatory framework
    • 7.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Norway
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Regulatory framework
    • 7.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.7. Sweden
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Regulatory framework
    • 7.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.8. Denmark
    • 7.5.8.1. Key country dynamics
    • 7.5.8.2. Competitive scenario
    • 7.5.8.3. Regulatory framework
    • 7.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Japan
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Competitive scenario
    • 7.6.1.3. Regulatory framework
    • 7.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. China
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. India
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. Australia
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Competitive scenario
    • 7.6.4.3. Regulatory framework
    • 7.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Competitive scenario
    • 7.6.5.3. Regulatory framework
    • 7.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6. Thailand
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Competitive scenario
    • 7.6.6.3. Regulatory framework
    • 7.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Brazil
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Competitive scenario
    • 7.7.1.3. Regulatory framework
    • 7.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Argentina
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. South Africa
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Competitive scenario
    • 7.8.1.3. Regulatory framework
    • 7.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.2. Saudi Arabia
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Competitive scenario
    • 7.8.2.3. Regulatory framework
    • 7.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.3. UAE
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Competitive scenario
    • 7.8.3.3. Regulatory framework
    • 7.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.4. Kuwait
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Competitive scenario
    • 7.8.4.3. Regulatory framework
    • 7.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2024
• 8.4. Company Profiles/Listing
  • 8.4.1. Creative Biolabs.
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. List Biological Labs, Inc.
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. The Native Antigen Company
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Bio-Techne.
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Abcam Plc.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. CAYMAN CHEMICAL
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Merck KGaA
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Enzo Life Sciences, Inc.
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Santa Cruz Biotechnology, Inc.
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Quadratech Diagnostics Ltd.
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives